Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement

Stock Track

02/28

ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.

The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.

Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1121764006"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121764006\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121764006?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121764006","market":"nz","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.</p><p>The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.</p><p>Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-28 07:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.</p><p>The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.</p><p>Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1121764006","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121764006","pubTimestamp":1772235669,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘后飙升5.11%，因即将发布业务更新和2025财年财务业绩公告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}